Search - tctmd.com

Displaying 81 - 100 of 145

Sort: Relevancy | Date

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News TCT 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Michael O'Riordan

November 06, 2021

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

Todd Neale

October 20, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

Shelley Wood

October 01, 2021

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Todd Neale

September 13, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2021

Shelley Wood

September 03, 2021

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

L.A. McKeown

August 10, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2021

Shelley Wood

August 02, 2021

News Daily News

Making the Case for Sex-Specific CVD Guidelines

L.A. McKeown

July 08, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Opinion CV Team Dispatch

June 2021 News Roundup

L.A. McKeown

June 01, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News EuroPCR 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

Michael O'Riordan

May 18, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

News Daily News

Pneumonia in HF Patients Is Common, Lethal, and Preventable

L.A. McKeown

April 19, 2021

Advertisement

Canagliflozin Improves Quality of Life in HF Patients

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

TCTMD’s Top 10 Most Popular Stories for September 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

TCTMD’s Top 10 Most Popular Stories for August 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

TCTMD’s Top 10 Most Popular Stories for July 2021

Making the Case for Sex-Specific CVD Guidelines

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

June 2021 News Roundup

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Elective Revascularization, Better Long-term Survival: Meta-analysis

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Pneumonia in HF Patients Is Common, Lethal, and Preventable

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content